Skip to content
IP + Technology Law
Home  »  News & Insights  »  News  »  Press Release

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States

October 20, 2014  | Joseph Mallon, Ph.D., Ryan E. Melnick, Ph.D., Kimberly J. Miller, Ph.D., Agnes Juang, Ph.D., Kerry S. Taylor, Ph.D., William Zimmerman, Rose M. Thiessen, Ph.D., Jing Liu, Jane Dai, Ph.D., Nathanael Luman, Ph.D., Victor C. Vassar and Vijay Gore, Ph.D.

Read the full press release here.

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Joseph Mallon, Ph.D.
Partner
San Diego
joseph.mallon@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Ryan E. Melnick, Ph.D.
Partner
San Diego
ryan.melnick@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Kimberly J. Miller, Ph.D.
Partner
San Diego
kimberly.miller@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Agnes Juang, Ph.D.
Partner
Orange County
agnes.juang@knobbe.com
949-760-0404
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

William Zimmerman
Partner
Washington DC
bill.zimmerman@knobbe.com
202-640-6400
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Jane Dai, Ph.D.
Partner
San Diego
jane.dai@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Nathanael Luman, Ph.D.
Partner
San Diego
nate.luman@knobbe.com
858-707-4000

Related Links

Industries

News & Insights

News
Jul 2026
Knobbe Martens Receives Top-Tier Recognitions in 2026 IP STARS Rankings by Managing IP
Firm sustains national top-tier rankings for patent prosecution and life sciences IP along with top state rankings for standout IP work; ten Knobbe Martens lawyers named “IP STARS” IRVINE, Calif.,...
News
Jul 2026
Knobbe Martens Secures TRO and Preliminary Injunction for Pacific Rim Capital in Trade Secret Misappropriation Case
IRVINE, Calif., July 23, 2026 – A team from Knobbe Martens secured a temporary restraining order (TRO) and Preliminary Injunction (PI) on behalf of Pacific Rim Capital, Inc. (PRC) in...
News
Aug 2026
Nine Knobbe Martens Partners Recognized in 2026 Lexology Index: IP Guide
IRVINE, Calif., August 12, 2026 – Leading intellectual property law firm Knobbe Martens is pleased to share that nine partners have been recognized in the 2026 edition of Lexology Index:...